Armis Advisers’s Pfizer PFE Stock Holding History

Armis Advisers’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-9,107	Closed	-$221K	–	457
2025 Q2	$221K	Buy	+9,107	New	+$212K	0.02%	426
2025 Q1	–	Sell	-8,095	Closed	-$215K	–	444
2024 Q4	$215K	Buy	+8,095	New	+$220K	0.03%	335

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Armis Advisers's PFE Position: Q3 2025 in Review

Armis Advisers sold out of Pfizer (PFE) in Q3 2025, closing a stake of 9,107 shares — an estimated $221K sold.

Armis Advisers first reported a position in PFE in Q4 2024 and held it in 2 quarters. The position peaked at $221K in Q2 2025. 2,812 funds tracked by Wall St. Rank hold PFE as of Q3 2025.

Armis Advisers reported no remaining Pfizer position as of Q3 2025 after selling out during the quarter.
Armis Advisers sold 9,107 Pfizer shares in Q3 2025, an estimated $221K.
Armis Advisers first reported a position in Pfizer in Q4 2024 and held it in 2 quarters.
Armis Advisers's Pfizer position peaked at $221K in Q2 2025.
2,812 funds tracked by Wall St. Rank held Pfizer as of Q3 2025.

Based on Armis Advisers's 13F filing for Q3 2025, filed 12 Nov 2025.